AMGN - AMGEN INC
303.25
-1.940 -0.640%
Share volume: 156,639
Last Updated: Wed 05 Feb 2025 04:30:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.12%
PREVIOUS CLOSE
CHG
CHG%
$305.19
-1.94
-0.64%
Fundamental analysis
44%
Profitability
36%
Dept financing
26%
Liquidity
19%
Performance
64%
Performance
5 Days
1.26%
1 Month
11.77%
3 Months
-9.48%
6 Months
-11.13%
1 Year
-10.23%
2 Year
18.52%
Key data
Stock price
$303.25
DAY RANGE
$284.93 - $306.28
52 WEEK RANGE
$253.30 - $346.85
52 WEEK CHANGE
-$2.32
DIVIDEND
$2.25
EX-DIVIDEND DATE
08/16/2024
NEXT EARNINGS DATE
N/A
Company detail
CEO: Robert A. Bradway
Region: US
Website: amgen.com
Employees: 25,200
IPO year: 1984
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: amgen.com
Employees: 25,200
IPO year: 1984
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. Its products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis. Repatha reduces the risks of myocardial infarction, stroke, and coronary revascularization.
Recent news